Veru Q2 net loss $2.7M; PLATEAU trial interim analysis expected Q1 2027

VERU INC.

Net loss $2.7M ($0.12/sh) vs $7.9M ($0.54) in Q2 2025; operating loss $7.2M.
Cash, equivalents & restricted cash $27.6M as of Mar 31, 2026, up from $15.8M Sep 30, 2025.
Phase 2b PLATEAU trial actively enrolling; interim analysis on lean/fat mass expected Q1 2027.
R&D expenses $3.1M (down from $3.9M); G&A $4.1M (down from $5.2M) vs year-ago quarter.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001193125-26-220569

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.